Thymosin Alpha-1

Name: Thymosin Alpha-1
Availability: InStock

5mg vial

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from prothymosin alpha, originally isolated from thymus tissue. It is one of the most studied immunomodulatory peptides, with clinical use in several countries for immune restoration, hepatitis, sepsis and as a vaccine adjuvant.

Select size

Checking availability…

Researched for

Enhanced T-cell maturation and Th1 immune polarisation
Improved dendritic-cell and natural-killer-cell activity
Adjuvant activity for vaccine and anti-infective research
Restored immune competence in age-related or stress-induced immunosenescence
Regulation of inflammatory cytokine balance
Extensive clinical safety data in approved indications outside the US

Mechanism of action

Modulates innate and adaptive immunity by promoting T-cell differentiation and maturation, enhancing dendritic-cell and natural-killer-cell activity, and normalising cytokine balance. Also upregulates toll-like receptor expression and supports Th1-polarised immune responses.

Research protocol

Common research protocols use 1.6mg subcutaneously twice weekly, or 1mg daily for short immune-support courses. Cycles typically run 4–12 weeks, with breaks between courses. Subcutaneous administration in the abdomen or thigh is standard.

Half-life

Plasma half-life approx. 2 hours; immunomodulatory effects persist for days through downstream cell signalling.

Reconstitution

Reconstitute a 5mg vial with 2–3mL bacteriostatic water for a 1.6–2.5mg/mL working concentration. Swirl gently.

Storage

Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 28 days.

Research considerations

• Mild injection-site reactions are the most common adverse event.
• Autoimmune conditions require caution due to immune-potentiating effects.
• Use as a standalone immune therapy should be guided by research context and monitoring.